Controlled Delivery of Antigens and Adjuvants in Vaccine Development
- 1 December 1996
- journal article
- review article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 85 (12), 1261-1270
- https://doi.org/10.1021/js9602812
Abstract
Advances in the understanding of the pathogenesis of infectious diseases and cancer immunology have inspired many new approaches to vaccine development. Many subunit antigens and peptides that are effective for vaccination have been discovered. These subunit antigens in tum stimulate synthesis of effective adjuvants to enhance their immunogenicity. Controlled-release technology offers the potential of further improving the efficacy of conventional vaccine formulations by optimizing the temporal and spatial presentation of the-antigens and adjuvants to the immune system. The combination of sustained release and depot effect may also reduce the amount of antigens or adjuvants needed and eliminate the booster shots that are necessary for the success of many vaccinations. This review examines the contribution controlled release technology can make in various areas of vaccination, with an emphasis on tumor vaccines.This publication has 100 references indexed in Scilit:
- Macrophage Colony-Stimulating Factor Complementary DNA: a Candidate for Gene Therapy in Metastatic MelanomaJNCI Journal of the National Cancer Institute, 1995
- Facilitated DNA inoculation induces anti-HIV-1 immunity in vivoVaccine, 1994
- Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccineVaccine, 1994
- Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide)Vaccine, 1993
- Immunotherapy Via Gene TherapyJournal of Immunotherapy, 1993
- Cytokine Production and Immune Cell Activation in Melanoma Patients Treated with Liposomal Muramyl Tripeptide (CGP 19835A Lipid)1Cancer Biotherapy, 1993
- Liposomes containing lipid A as a potent non-toxic adjuvantResearch in Immunology, 1992
- Immunological adjuvants: a role for liposomesImmunology Today, 1990
- Importance of physical association between antigen and liposomes in liposomes adjuvanticityImmunology Letters, 1989
- Hepatitis B surface antigen‐containing liposomes enhance humoral and cell‐mediated immunity to the antigenFEBS Letters, 1979